No Carolina / NY / Florida
Ph: 561.316.3330

MAGNEZIX CS 3.2 Granted Designation as a “Breakthrough Device” by the U.S. FDA Reports Syntellix AG

Summation

  • Of regulatory authorities in the world has classified our implant as a ‘Breakthrough Device’, which by definition of the relevant FDA criteria implies more effective treatment of life-threatening or irreversibly debilitating human disease or conditions.
  • I am sure that the FDA decision will act as a reference and catalyst for patients, doctors, healthcare providers, and healthcare authorities around the globe.
  • MAGNEZIX based implant had to meet tough criteria and thus prove that it “provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions”.

October 30, 2020

MAGNEZIX CS 3.2 device has been granted designation as a”Breakthrough Device” by the U.S. Food and Drug Administration. Syntellix announced the news today.

MAGNEZIX based implant had to meet tough criteria and thus prove that it “provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions” and, additionally, that it either “represents breakthrough technology”, “offers significant advantages over existing approved or cleared alternatives” or that its “availability is in the best interest of patients”.

Syntellix CEO and Chairman of the Executive Board Prof. Dr. Utz Claassen commented the breaking news for the company as follows: “We feel very honored by the fact that the institution which we deeply respect as the ‘Cathedral’ of regulatory authorities in the world has classified our implant as a ‘Breakthrough Device’, which by definition of the relevant FDA criteria implies more effective treatment of life-threatening or irreversibly debilitating human disease or conditions. The COVID-19 pandemic has brought infection risks into the focus of public interest. Therefore, our products, which naturally avoid implant removal surgeries and related risks, as well as their life-saving character become even more relevant as an elementary building block for healthcare systems worldwide. I am sure that the FDA decision will act as a reference and catalyst for patients, doctors, healthcare providers, and healthcare authorities around the globe.”

Other FDA News of Interest

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

By using this website you agree to accept Medical Device News Magazine Privacy Policy